10-Q: Cerenome Reports Q3 2026 Results, Faces Nasdaq Scrutiny

Cerenome, Inc. (CNSY) filed its Q3 2026 Form 10-Q, detailing a significant net loss, ongoing liquidity concerns, and potential Nasdaq delisting, while also reporting initial diagnostic revenue and progress in its therapeutic pipeline.

Summary

• Cerenome, Inc. reported its quarterly results for the period ending September 30, 2026.
• The company experienced a net loss of $8.66 million for the three months ended September 30, 2026, and a net loss of $24.61 million for the nine months ended September 30, 2026.
• Total revenue for the three months ended September 30, 2026, was $0.72 million, primarily from diagnostic revenue, a significant decrease from $1.40 million in the prior year period.
• Grant revenue decreased significantly, while diagnostic revenue was newly recognized.
• The company has substantial accumulated deficits and faces substantial doubt about its ability to continue as a going concern.
• Cerenome expects to receive a notice from Nasdaq indicating non-compliance with the Minimum Stockholders Equity Requirement.
• The company secured $2.8 million in net proceeds from the Initial Note of a senior secured convertible note agreement with 3i, LP.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to significant net losses, a precarious going concern status, and potential Nasdaq delisting risks, despite progress in diagnostic revenue and clinical trials.

Positives

• The company began commercial billing for its CNSide diagnostic testing services, recognizing $0.72 million in diagnostic revenue for the three and nine months ended September 30, 2026.
• The CNSide platform received a dedicated PLA code (0640U) from the AMA, effective July 1, 2026, and a favorable preliminary payment determination from CMS for Medicare.
• The ReSPECT-LM Phase 1 clinical trial was completed, showing REYOBIQ was well-tolerated and determining a recommended Phase 2 dose.
• The ReSPECT-GBM Phase 2 trial enrolled 32 of 34 planned patients, with interim data showing promising safety and efficacy indicators.
• The company completed an underwritten public offering in January 2026, raising approximately $13.9 million in net proceeds.
• The company entered into an Equity Distribution Agreement in June 2026, allowing for at-the-market offerings up to $17.35 million, and raised $3.1 million under this agreement.

Negatives

• The company reported a net loss of $8.66 million for the three months ended September 30, 2026, and a net loss of $24.61 million for the nine months ended September 30, 2026.
• Total revenue decreased to $0.72 million in the three months ended September 30, 2026, from $1.40 million in the same period of 2025.
• The company has substantial accumulated deficits ($540.5 million as of September 30, 2026) and faces substantial doubt about its ability to continue as a going concern.
• Cerenome expects to receive a notice from Nasdaq indicating non-compliance with the Minimum Stockholders Equity Requirement, potentially leading to delisting.
• Cash and cash equivalents, restricted cash, and total assets have significantly decreased compared to the prior year.
• Working capital was negative $5.06 million as of September 30, 2026, compared to positive $2.53 million as of December 31, 2025.

Risks

• Failure to comply with Nasdaq continued listing requirements could lead to delisting, negatively impacting stock price and capital access.
• The company's ability to generate meaningful revenue from the CNSide Platform is uncertain and depends on reimbursement, collections, and market adoption.
• The company may not receive all or any portion of the remaining funding available under its existing financing arrangements.
• The company has a history of operating losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern.
• The early stage of product candidates and therapies, and uncertainties in clinical trials, pose significant risks.
• Competition from other companies in the radiotherapeutics and diagnostics fields is intense.
• The company's ability to obtain and maintain regulatory approvals for its product candidates is not guaranteed.
• The company's success is dependent on its ability to raise additional capital in the future.

Future Outlook

The company requires significant additional capital to fund its ongoing clinical development programs, commercialization of the CNSide Test, and other operations. Future funding needs will depend on clinical trial progress, regulatory approvals, commercial success of CNSide, and other factors. There is no assurance that additional capital will be available on acceptable terms or at all, which could materially adversely affect operations and compliance with listing rules.

Management Comments

• Cerenome is a U.S. pharmaceutical and diagnostics company developing targeted radiotherapeutics and advanced diagnostic platform technologies for central nervous system (CNS) cancers.
• Our therapeutic and diagnostic programs are designed to improve the detection, characterization, and treatment of aggressive CNS malignancies, including primary brain tumors and metastatic disease involving the CNS.
• The CNSide diagnostic platform represents a strategic expansion of the Company's business beyond therapeutics into CNS-focused diagnostics.
• The Company believes that the CNSide Platform has the potential to complement its radiotherapeutic development programs by improving disease detection, molecular characterization, patient stratification, and treatment monitoring in CNS cancers.

Industry Context

StockSavvy.ai notes that Cerenome operates in the highly competitive and regulated CNS oncology market, facing challenges from both established pharmaceutical companies and emerging biotechnology firms. The company's dual focus on diagnostics (CNSide) and therapeutics (REYOBIQ) reflects a trend towards integrated approaches in cancer care, aiming to improve patient stratification and treatment efficacy.

Comparison to Industry Standards

• In the recurrent glioblastoma space, competitors like Telix Pharmaceuticals are also developing targeted radiopharmaceutical therapies, with TLX101-Tx in Phase 3 evaluation.
• For leptomeningeal metastases, companies such as Telix Pharmaceuticals (TLX102-Tx), AstraZeneca, and Daiichi Sankyo are pursuing various treatment modalities including radiopharmaceuticals and antibody-drug conjugates.
• In pediatric brain cancer, Jazz Pharmaceuticals and Servier (via Day One Biopharmaceuticals) have marketed products for specific pediatric brain tumors.
• For liver cancer radioembolization, companies like Boston Scientific and Sirtex Medical offer competing technologies.
• In the diagnostics space, companies like Belay Diagnostics, Lucence, and Genomic Testing Cooperative offer competing CSF-based molecular profiling tests.

Stakeholder Impact

• Shareholders may experience continued stock price volatility due to financial performance, Nasdaq listing concerns, and ongoing capital needs.
• Investors in the convertible note agreement with 3i, LP are subject to conversion and redemption terms, as well as royalty obligations.
• Employees may face uncertainty due to the company's going concern status and potential need for operational reductions.
• Customers (healthcare providers) ordering the CNSide Test are subject to evolving reimbursement and coverage decisions.
• Creditors and suppliers may face risks related to the company's liquidity and ability to meet its financial obligations.

Next Steps

• Continue clinical development programs for REYOBIQ and other therapeutic candidates.
• Further develop and commercialize the CNSide Platform, including expanding payer coverage and reimbursement.
• Address Nasdaq's continued listing requirements and work towards regaining compliance.
• Seek additional capital through equity offerings, debt financings, or collaborations.
• Prepare for data read-out from the ReSPECT-GBM Phase 2 trial in the first half of 2027.
• Obtain New York State Department of Health permit for CNSide testing.
• Launch CNSide CSF Cellular Biomarkers in the fourth quarter of 2026.
• Finalize data review and prepare clinical study report and manuscript for the ReSPECT-LM Phase 1 trial.

Key Dates

Recommendation

The company exhibits significant financial distress, including substantial net losses, a negative going concern status, and an imminent risk of Nasdaq delisting. While there are promising developments in diagnostics and clinical trials, these are overshadowed by the immediate financial and regulatory challenges. The need for continuous capital raises is dilutive and uncertain. Therefore, a sell recommendation is warranted for risk-averse investors.

Keywords

radiotherapeutics, CNS cancer, diagnostics, glioblastoma, leptomeningeal metastases, pediatric brain cancer, CNSide, REYOBIQ